What a milestone! With the first commercial product order accepted, $ADAP looks forward to bringing this newly FDA-approved cell therapy to more patients in need. https://t.co/6tbvZ36Cl7 #CellTherapy #Biotech #Innovation

ICYMI: $ADAP received @US_FDA accelerated approval for the first engineered cell therapy for the treatment of a solid tumor cancer. Announcement here: https://t.co/JlHWW1YAgG #celltherapy #biotech #oncology

#BreakingNews @GalapagosGlobal and $ADAP sign clinical collaboration and exclusive option to license agreement for TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications. https://t.co/qRTecRbNcH A live webcast will be held on

Today $ADAP reported financial results for Q4 and full year ended Dec. 31, 2023, and provided a business update on the progress made in establishing our sarcoma franchise. Release: https://t.co/zpQUfBSCu2 Call replay: https://t.co/zMbLwE62Vm #biotech #celltherapy #sarcoma

Today $ADAP reported financial results for Q4 and full year ended Dec. 31, 2023, and provided a business update on the progress made in establishing our sarcoma franchise. Release: https://t.co/zpQUfBSCu2 Call replay: https://t.co/zMbLwE62Vm #biotech #celltherapy #sarcoma

Please join us in welcoming back Cintia Piccina as $ADAP Chief Commercial Officer! Effective March 18, 2024, Cintia returns to lead a rapidly expanding commercial team as it prepares for the launch of afami-cel which, once approved, will be the first engineered TCR T-cell therapy

BREAKING NEWS: FDA accepts $ADAP application for our investigational engineered T-cell therapy for the treatment of #synovialsarcoma with priority review. Press release here: https://t.co/mkUGQyoMNb #biotech #fda

$ADAP ICYMI – replay ( https://t.co/fAzNXxDXJQ) of our presentation at #JPMHC24 – where we outlined our near- and long-term value proposition with our wholly owned cell therapy pipeline. Email investor.relations@adaptimmune.com to schedule time with management.

$ADAP CEO Adrian Rawcliffe spoke today at #JPMHC24 about the company’s sarcoma franchise and work from discovery to delivery of cell therapies with the potential to redefine the treatment of solid tumors. #celltherapy #oncology #biotechnology

$ADAP aims to redefine cancer treatment in solid tumors with cell therapy. For meetings with management email: investor.relations@adaptimmune.com. Presenting at #JPM2024 #JPM24

Our CEO, Adrian Rawcliffe, will present Adaptimmune’s 2024 plans at the J.P. Morgan Healthcare Conference next Thursday, January 11th from 8:15 to 8:55 a.m. PST. Release here: https://t.co/ekD0FaLbif. The presentation can be accessed live from the Westin, San Francisco or at the

$ADAP today announced the completion of the rolling Biologics License Application (BLA) to the FDA for an investigational engineered T-cell therapy for the treatment of advanced #SynovialSarcoma! The first ever BLA to be submitted for an engineered T-cell therapy for solid

Today, we announced completion of the transfer of the IND for letetresgene autoluecel (lete-cel) from GSK to $ADAP for the pivotal IGNYTE-ESO (NCT03967223) clinical trial. Data from this trial frame lete-cel as a synergistic product to afami-cel within our cell therapy pipeline.

ICYMI: $ADAP today announced selection of ADP-600 as a clinical candidate for its best-in-class PRAME strategy. See release for details: https://t.co/3hNP63wAD1

#News: Today, $ADAP provided its Q3 2023 financial and business update. Release and details for replay can be accessed here: https://t.co/kjE6TJq6zE #earnings #celltherapy #biotechnology

$ADAP and @bvantine1 to present SPEARHEAD-1 trial long-term outcomes data at the #CTOS 2023 Annual Meeting. 39% of patients who received ADAP treatment had clinical responses. 70% of people with advanced disease who responded to ADAP treatment are alive 2 years post-treatment.

$ADAP today presented clinical and translational data from the Ph 1 SURPASS clinical trial at #ESMO23. Data show a 50% response rate in 26 patients with ovarian, urothelial, and head & neck cancers and 75% response rate in these three cancers in patients who received three or